Tanigaki N, Tosi R, Centis D, Ferrara G B
Hum Immunol. 1985 Jan;12(1):47-57. doi: 10.1016/0198-8859(85)90253-8.
Antiserum 8w670 which had been classified as anti-DR5 in the Workshop analysis was found by the direct binding test to react with about 40% of Ia molecules in an Ia preparation from LG38 cells (DR5,5) that was deleted of DR molecules and DR-like molecules we call BR and enriched in DC molecules by pretreatment with a rabbit antiserum raised against alpha-subunits of DR and BR molecules. The specificity involved in the binding reaction was shown by the binding inhibition assay to be present in 100% of DR5-positive cases (53 out of 53) and 8w13-positive cases (2 out of 2) and in 23% of DR4-positive cases (4 out of 17). This association pattern did not correspond to any of the known supertypic specificities including the DC beta 4 and DC alpha 3, both of which had been found on DR5-associated DC molecules. Yet sequential binding analysis revealed that the 8w670-defined specificity was indeed present on the same molecules carrying DC beta 4 and DC alpha 3 specificities. This specificity was designated DC5.
在研讨会上被归类为抗DR5的抗血清8w670，通过直接结合试验发现，它能与来自LG38细胞（DR5,5）的Ia制剂中约40%的Ia分子发生反应，该制剂中的DR分子和我们称为BR的DR样分子已被去除，并通过用针对DR和BR分子α亚基的兔抗血清预处理而富集了DC分子。结合抑制试验表明，结合反应所涉及的特异性在100%的DR5阳性病例（53例中的53例）和8w13阳性病例（2例中的2例）以及23%的DR4阳性病例（17例中的4例）中存在。这种关联模式与任何已知的超型特异性均不对应，包括DCβ4和DCα3，这两者都已在与DR5相关的DC分子上被发现。然而，序列结合分析表明，8w670定义的特异性确实存在于携带DCβ4和DCα3特异性的相同分子上。这种特异性被命名为DC5。
